The Application of Mesenchymal Stem Cells in Different Cardiovascular Disorders: Ways of Administration, and the Effectors
Author:
- 18 July 2024
- journal article
- review article
- Published by Springer Nature in Stem Cell Reviews and Reports
- Vol. 20 (7) , 1671-1691
Abstract
The heart is an organ with a low ability to renew and repair itself. MSCs have cell surface markers such as CD45−, CD34−, CD31−, CD4+, CD11a+, CD11b+, CD15+, CD18+, CD25+, CD49d+, CD50+, CD105+, CD73+, CD90+, CD9+, CD10+, CD106+, CD109+, CD127+, CD120a+, CD120b+, CD124+, CD126+, CD140a+, CD140b+, adherent properties and the ability to differentiate into cells such as adipocytes, osteoblasts and chondrocytes. Autogenic, allogeneic, normal, pretreated and genetically modified MSCs and secretomes are used in preclinical and clinical studies. MSCs and their secretomes (the total released molecules) generally have cardioprotective effects. Studies on cardiovascular diseases using MSCs and their secretomes include myocardial infraction/ischemia, fibrosis, hypertrophy, dilated cardiomyopathy and atherosclerosis. Stem cells or their secretomes used for this purpose are administered to the heart via intracoronary (Antegrade intracoronary and retrograde coronary venous injection), intramyocardial (Transendocardial and epicardial injection) and intravenous routes. The protective effects of MSCs and their secretomes on the heart are generally attributed to their differentiation into cardiomyocytes and endothelial cells, their immunomodulatory properties, paracrine effects, increasing blood vessel density, cardiac remodeling, and ejection fraction and decreasing apoptosis, the size of the wound, end-diastolic volume, end-systolic volume, ventricular myo-mass, fibrosis, matrix metalloproteins, and oxidative stress. The present review aims to assist researchers and physicians in selecting the appropriate cell type, secretomes, and technique to increase the chance of success in designing therapeutic strategies against cardiovascular diseases. Graphical Abstract As a result of the application of MSCs and MSC secretomes, the red side shows reducing properties and the green side shows increasing propertiesKeywords
This publication has 112 references indexed in Scilit:
- MESENCHYMAL STEM CELLS PROMOTE CARDIOMYOCYTE HYPERTROPHY IN VITRO THROUGH HYPOXIA‐INDUCED PARACRINE MECHANISMSClinical and Experimental Pharmacology and Physiology, 2009
- Mesenchymal stem cell transplantation attenuates cardiac fibrosis associated with isoproterenol-induced global heart failureTransplant International, 2008
- Mesenchymal stem cells and cardiac repairJournal of Cellular and Molecular Medicine, 2008
- Mesenchymal stem cell administration at coronary artery reperfusion in the rat by two delivery routes: A quantitative assessmentLife Sciences, 2008
- Comparison of intracoronary and transendocardial delivery of allogeneic mesenchymal cells in a canine model of acute myocardial infarctionJournal of Molecular and Cellular Cardiology, 2008
- Improvement in hemodynamic performance, exercise capacity, inflammatory profile, and left ventricular reverse remodeling after intracoronary delivery of mesenchymal stem cells in an experimental model of pressure overload hypertrophyThe Journal of Thoracic and Cardiovascular Surgery, 2008
- Placental mesenchymal and cord blood stem cell therapy for dilated cardiomyopathyReproductive BioMedicine Online, 2008
- Oxidative stress and redox signalling in cardiac hypertrophy and heart failureHeart, 2006
- Transplantation of Mesenchymal Stem Cells Improves Cardiac Function in a Rat Model of Dilated CardiomyopathyCirculation, 2005
- Catheter-based antegrade intracoronary viral gene delivery with coronary venous blockadeAmerican Journal of Physiology-Heart and Circulatory Physiology, 2005